Oncopeptides AB (publ) announced that Sofia Heigis who will move from the CCO role to take on the CEO role.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.34 SEK | +4.70% | +17.19% | -56.40% |
30/05 | Oncopeptides Issues Warrants Under Loan Deal with European Investment Bank | MT |
30/05 | Transcript : Oncopeptides AB, Q1 2024 Earnings Call, May 30, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.40% | 65.9M | |
+15.41% | 121B | |
+13.47% | 107B | |
-5.06% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.50% | 15.31B | |
+2.93% | 14.08B | |
+24.84% | 11.74B |
- Stock Market
- Equities
- ONCO Stock
- News Oncopeptides AB
- Oncopeptides AB Announces Sofia Heigis to Move from the CCO Role to CEO Role